For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...

The astraszenecaglobal.xyz scam is abusing the real pharmaceutical giant’s name to run a fake investment scheme targeting ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...